- ►uic.edu [PDF] KG Saag, R Emkey, TJ Schnitzer, JP Brown, F … - New England Journal …, 1998 - content.nejm.org ABSTRACT Background Osteoporosis is a common compli- cation of long-term glucocorticoid
therapy for which there is no well-proved preventive or restorative treatment. Methods We carried
out two 48-week, random- ized, placebo-controlled studies of two doses of alendronate in ... Cited by 739 - Related articles - BL Direct - All 10 versions
- ►nih.gov [PDF] RS Weinstein, RL Jilka, AM Parfitt, SC … - Journal of Clinical …, 1998 - Am Soc Clin Investig Glucocorticoid-induced bone disease is characterized by decreased bone formation and in situ
death of isolated segments of bone (osteonecrosis) suggesting that glucocorticoid excess, the
third most common cause of osteoporosis, may affect the birth or death rate of bone cells, ... Cited by 671 - Related articles - BL Direct - All 12 versions
- ►robarts.ca [PDF] BG Feagan, J Rochon, RN Fedorak, EJ Irvine, … - New England Journal …, 1995 - content.nejm.org Methods We conducted a double-blind, placebo-controlled multicenter study of weekly injections
of methotrexate in patients who had chronically active Crohn's disease despite a minimum of
three months of prednisone therapy. Patients were randomly assigned to treatment with ... Cited by 588 - Related articles - BL Direct - All 8 versions
- ►psu.edu [PDF] JD Adachi, WG Bensen, J Brown, D Hanley, … - The New England …, 1997 - nejm.highwire.org Background and Methods Osteoporosis is a recognized complication of corticosteroid
therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized,
placebo-controlled study of intermittent etidronate (400 mg per day for 14 days) followed ... Cited by 580 - Related articles - BL Direct - All 9 versions
- ►annals.org DT Boumpas, GP Chrousos, RL Wilder, TR … - Annals of internal …, 1993 - Am Coll Physicians Glucocorticoids are pleiotropic hormones that at pharmacologic doses prevent or suppress inflammation
and other immunologically mediated processes. At the molecular level, glucocorticoids form
complexes with specific receptors that migrate to the nucleus where they interact with ... Cited by 437 - Related articles - All 5 versions
- ►endojournals.org S Khosla - Endocrinology, 2001 - Endocrine Soc The identification of the OPG/RANKL/RANK system as the dominant, final mediator of osteoclastogenesis
represents a major advance in bone biology. It ended a long-standing search for the specific
factor produced by preosteoblastic/stromal cells that was both necessary and sufficient for ... Cited by 387 - Related articles - BL Direct - All 4 versions
- ►endojournals.org LC Hofbauer, F Gori, BL Riggs, DL Lacey, CR Dunstan, … - Endocrinology, 1999 - Endocrine Soc Osteoporosis is a serious complication of systemic glucocorticoid use. However, while glucocorticoids
increase bone resorption in vitro and in vivo, the mechanism(s) of this effect are at present
unclear. Recent studies have identified the osteoprotegerin (OPG) ligand (OPG-L) as the ... Cited by 369 - Related articles - BL Direct - All 5 versions
- ►nih.gov [PDF] NE Lane, S Sanchez, GW Modin, HK … - Journal of Clinical …, 1998 - pubmedcentral.nih.gov Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We
conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH
1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were ... Cited by 362 - Related articles - BL Direct - All 10 versions
E Canalis - J Clin Endocrinol Metab, 1996 - Endocrine Soc Bone remodeling is regulated by systemic hormones and locally produced factors acting in concert
to maintain bone mass (1). In the adult skeleton, bone remodeling is a tightly controlled process
that occurs in the bone surface and results in bone turnover. Bone formation occurs only ... Cited by 292 - Related articles - BL Direct - All 8 versions
